14-day Premium Trial Subscription Try For FreeTry Free

Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of CANF
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Wednesday for Can-Fite BioPharma Ltd stock after losing 1.52%
(Updated on Apr 24, 2024)

Sell candidate since Apr 17, 2024 Loss -1.02% PDF

The Can-Fite BioPharma Ltd stock price fell by -1.52% on the last day (Wednesday, 24th Apr 2024) from $1.97 to $1.94. During the last trading day the stock fluctuated 1.03% from a day low at $1.94 to a day high of $1.96. The price has fallen in 6 of the last 10 days and is down by -17.45% for this period. Volume has increased on the last day by 2 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 6 thousand shares were bought and sold for approximately $11.14 thousand.

Given the current short-term trend, the stock is expected to rise 5.43% during the next 3 months and, with a 90% probability hold a price between $2.05 and $2.56 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

CANF Signals & Forecast

There are few to no technical positive signals at the moment. The Can-Fite BioPharma Ltd stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $1.98 and $2.18. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Monday, April 08, 2024, and so far it has fallen -19.17%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Can-Fite BioPharma Ltd gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Can-Fite BioPharma Ltd stock

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.0200 between high and low, or 1.03%. For the last week, the stock has had daily average volatility of 3.48%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (CANF) For The Upcoming Trading Day Of Thursday 25th

For the upcoming trading day on Thursday, 25th we expect Can-Fite BioPharma Ltd to open at $1.95, and during the day (based on 14 day Average True Range), to move between $1.80 and $2.08, which gives a possible trading interval of +/-$0.138 (+/-7.13%) up or down from last closing price. If Can-Fite BioPharma Ltd takes out the full calculated possible swing range there will be an estimated 14.26% move between the lowest and the highest trading price during the day.

With no support below and resistance from accumulated volume @ $2.06, some $0.120 (6.19%) from the current price of $1.94, our system finds the risk reward not very attractive.

Is Can-Fite BioPharma Ltd stock A Buy?

The Can-Fite BioPharma Ltd stock holds several negative signals and despite the positive trend, we believe Can-Fite BioPharma Ltd will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -4.256 Sell Candidate Unchanged

Predicted Opening Price for Can-Fite BioPharma Ltd of Thursday, April 25, 2024

Fair opening price April 25, 2024 Current price
$1.95 ( 0.344%) $1.94

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for CANF

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 1.97 1.37 %
R2 1.96 0.98 %
R1 1.95 0.737 %
Current price: 1.94
Support S1 1.94 -0.0502 %
S2 1.93 -0.293 %
S3 1.93 -0.687 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 2.11 8.51 %
R2 2.10 8.25 %
R1 2.06 6.19 %
Current price 1.94
Support S1 0 .
S2 0 .
S3 0 .

FAQ

What is the symbol for Can-Fite BioPharma Ltd Stock and on which exchange is it traded?
The symbol for Can-Fite BioPharma Ltd is CANF and it is traded on the NYSEMKT (NYSE American).

Should I buy or sell Can-Fite BioPharma Ltd Stock?
The Can-Fite BioPharma Ltd stock holds several negative signals and despite the positive trend, we believe Can-Fite BioPharma Ltd will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy Can-Fite BioPharma Ltd Stock?
Can-Fite BioPharma Ltd Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Can-Fite BioPharma Ltd Stock.

What's the current price of Can-Fite BioPharma Ltd Stock?
As of the end of day on the Apr 24, 2024, the price of an Can-Fite BioPharma Ltd (CANF) share was $1.94.

What is the 52-week high and low for Can-Fite BioPharma Ltd Stock?
The 52-week high for Can-Fite BioPharma Ltd Stock is $3.33 and the 52-week low is $1.71.

What is the market capitalization of Can-Fite BioPharma Ltd Stock?
As of the Apr 24, 2024, the market capitalization of Can-Fite BioPharma Ltd is 10.799M.

When is the next earnings date for Can-Fite BioPharma Ltd?
The upcoming earnings date for Can-Fite BioPharma Ltd is Jun 06, 2024.
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT